Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Down 6.3% – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares fell 6.3% during mid-day trading on Monday . The company traded as low as $16.07 and last traded at $16.09. 1,724 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 370,734 shares. The stock had previously closed at $17.18.

Analyst Upgrades and Downgrades

DSNKY has been the subject of a number of recent research reports. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce”.

Daiichi Sankyo Trading Up 0.6%

The firm has a 50-day moving average of $16.73 and a 200-day moving average of $17.40. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42. The firm has a market capitalization of $31.45 billion, a P/E ratio of 19.63, a price-to-earnings-growth ratio of 3.31 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities research analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.